Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: AGR2

Gene summary for AGR2

Gene summary.

Gene information	Species	Human
	Gene symbol	AGR2
	Gene ID	10551
	Gene name	anterior gradient 2, protein disulphide isomerase family member
	Gene Alias	AG-2
	Cytomap	7p21.1
	Gene Type	protein-coding
	GO ID	GO:0002065
	UniProtAcc	O95994

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
10551	AGR2	GSM4909281	Human	Breast	IDC	8.10e-07	-2.72e-01	0.21
10551	AGR2	GSM4909282	Human	Breast	IDC	5.64e-06	-2.44e-01	-0.0288
10551	AGR2	GSM4909285	Human	Breast	IDC	6.94e-03	-2.49e-01	0.21
10551	AGR2	GSM4909286	Human	Breast	IDC	8.32e-08	-2.73e-01	0.1081
10551	AGR2	GSM4909287	Human	Breast	IDC	3.74e-03	-2.61e-01	0.2057
10551	AGR2	GSM4909290	Human	Breast	IDC	3.04e-02	3.04e-01	0.2096
10551	AGR2	GSM4909293	Human	Breast	IDC	2.39e-09	3.36e-01	0.1581
10551	AGR2	GSM4909294	Human	Breast	IDC	5.35e-05	4.10e-01	0.2022
10551	AGR2	GSM4909295	Human	Breast	IDC	9.25e-03	-2.89e-01	0.0898
10551	AGR2	GSM4909297	Human	Breast	IDC	4.45e-13	6.34e-01	0.1517
10551	AGR2	GSM4909298	Human	Breast	IDC	2.50e-02	1.54e-01	0.1551
10551	AGR2	GSM4909302	Human	Breast	IDC	1.39e-03	3.91e-01	0.1545
10551	AGR2	GSM4909303	Human	Breast	IDC	4.24e-02	4.53e-01	0.0438
10551	AGR2	GSM4909304	Human	Breast	IDC	3.52e-44	9.43e-01	0.1636
10551	AGR2	GSM4909305	Human	Breast	IDC	2.74e-03	2.17e-01	0.0436
10551	AGR2	GSM4909306	Human	Breast	IDC	5.21e-11	4.67e-01	0.1564
10551	AGR2	GSM4909307	Human	Breast	IDC	3.51e-34	9.15e-01	0.1569
10551	AGR2	GSM4909308	Human	Breast	IDC	3.59e-99	1.45e+00	0.158
10551	AGR2	GSM4909309	Human	Breast	IDC	5.38e-20	7.67e-01	0.0483
10551	AGR2	GSM4909311	Human	Breast	IDC	2.29e-03	-1.52e-01	0.1534

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:003596725	Esophagus	HGIN	cellular response to topologically incorrect protein	41/2587	116/18723	4.07e-09	2.84e-07	41
GO:003462020	Esophagus	HGIN	cellular response to unfolded protein	36/2587	96/18723	5.82e-09	3.88e-07	36
GO:190589725	Esophagus	HGIN	regulation of response to endoplasmic reticulum stress	31/2587	82/18723	5.25e-08	2.91e-06	31
GO:000698410	Esophagus	HGIN	ER-nucleus signaling pathway	19/2587	46/18723	4.28e-06	1.41e-04	19
GO:007265920	Esophagus	HGIN	protein localization to plasma membrane	66/2587	284/18723	1.11e-05	3.18e-04	66
GO:003096817	Esophagus	HGIN	endoplasmic reticulum unfolded protein response	24/2587	74/18723	3.39e-05	8.61e-04	24
GO:190547518	Esophagus	HGIN	regulation of protein localization to membrane	43/2587	175/18723	9.45e-05	2.03e-03	43
GO:199077818	Esophagus	HGIN	protein localization to cell periphery	71/2587	333/18723	1.05e-04	2.24e-03	71
GO:00364996	Esophagus	HGIN	PERK-mediated unfolded protein response	9/2587	18/18723	2.70e-04	4.67e-03	9
GO:190307619	Esophagus	HGIN	regulation of protein localization to plasma membrane	28/2587	104/18723	3.07e-04	5.15e-03	28
GO:190437518	Esophagus	HGIN	regulation of protein localization to cell periphery	32/2587	125/18723	3.23e-04	5.39e-03	32
GO:01404675	Esophagus	HGIN	integrated stress response signaling	9/2587	22/18723	1.64e-03	1.82e-02	9
GO:19058985	Esophagus	HGIN	positive regulation of response to endoplasmic reticulum stress	12/2587	35/18723	1.80e-03	1.94e-02	12
GO:003812717	Esophagus	HGIN	ERBB signaling pathway	29/2587	121/18723	1.83e-03	1.97e-02	29
GO:190547718	Esophagus	HGIN	positive regulation of protein localization to membrane	26/2587	106/18723	2.17e-03	2.25e-02	26
GO:00604794	Esophagus	HGIN	lung cell differentiation	9/2587	24/18723	3.33e-03	3.12e-02	9
GO:19011848	Esophagus	HGIN	regulation of ERBB signaling pathway	20/2587	79/18723	4.56e-03	3.96e-02	20
GO:190437718	Esophagus	HGIN	positive regulation of protein localization to cell periphery	18/2587	69/18723	4.94e-03	4.18e-02	18
GO:000717317	Esophagus	HGIN	epidermal growth factor receptor signaling pathway	25/2587	108/18723	5.87e-03	4.77e-02	25
GO:0034976111	Esophagus	ESCC	response to endoplasmic reticulum stress	192/8552	256/18723	7.15e-22	1.30e-19	192

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

AGR2

SNV

Missense_Mutation

rs375782337

c.418G>A

p.Asp140Asn

p.D140N

O95994

protein_coding

deleterious(0)

probably_damaging(0.956)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

AGR2

SNV

Missense_Mutation

novel

c.226N>G

p.His76Asp

p.H76D

O95994

protein_coding

deleterious(0.01)

probably_damaging(0.964)

TCGA-JW-A5VL-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

AGR2

SNV

Missense_Mutation

c.281N>G

p.Asn94Ser

p.N94S

O95994

protein_coding

tolerated(0.87)

benign(0)

TCGA-CA-6718-01

Colorectum

colon adenocarcinoma

Male

<65

I/II

Unknown

AGR2

SNV

Missense_Mutation

rs755871634

c.443N>A

p.Arg148His

p.R148H

O95994

protein_coding

tolerated(0.14)

benign(0.006)

TCGA-AP-A1DK-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

AGR2

SNV

Missense_Mutation

c.93G>T

p.Lys31Asn

p.K31N

O95994

protein_coding

tolerated(0.05)

benign(0.444)

TCGA-AX-A0J0-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

AGR2

SNV

Missense_Mutation

novel

c.31C>A

p.Leu11Ile

p.L11I

O95994

protein_coding

deleterious(0.03)

benign(0.048)

TCGA-AX-A2HC-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

paclitaxel

AGR2

SNV

Missense_Mutation

c.457N>A

p.Glu153Lys

p.E153K

O95994

protein_coding

tolerated(0.09)

benign(0.227)

TCGA-AX-A2HD-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

III/IV

Unknown

AGR2

SNV

Missense_Mutation

c.264N>T

p.Lys88Asn

p.K88N

O95994

protein_coding

deleterious(0)

probably_damaging(0.942)

TCGA-AX-A2HD-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

III/IV

Unknown

AGR2

SNV

Missense_Mutation

rs755871634

c.443N>A

p.Arg148His

p.R148H

O95994

protein_coding

tolerated(0.14)

benign(0.006)

TCGA-BG-A0LX-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

AGR2

SNV

Missense_Mutation

c.264N>T

p.Lys88Asn

p.K88N

O95994

protein_coding

deleterious(0)

probably_damaging(0.942)

TCGA-D1-A103-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1